약물 관련 악골괴사와 연관된 위험인자와 골밀도에 관한 연구
The Study of the Risk Factors and Bone Mineral Density Related to Medication-related Osteonecrosis of the Jaw
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
To examine risk factors of MRONJ and compare whether there is a difference in BMD value depending on the duration of administration, method of administration, and occurrence of MRONJ. We selected 53 patients who were diagnosed with MRONJ at the Ulsan University Hospital and underwent surgery between January 2011 and May 2021. The risk factors are age, sex, systemic disease, location, administration methods, type of drug, duration, local factors and stage. 19 patients, especially those who were diagnosed with MRONJ and underwent BMD, were compared with BMD in femur and lumbar areas according to duration, administration methods. There were many women in all age groups, with 18 in their 70s. There were about twice as many mandibles as the maxilla. It was significantly higher when the IV BPs was administered in cancer patients, and significantly higher when the oral BPs was administered in osteoporosis patients. There was a significant difference between each period in patients taking oral BPs, and the incidence of MRONJ was high when taking them for more than 4 years. There were 35 patients who developed into MRONJ after dentoalveolar surgery. There were significant differences in femur and lumbar BMD, T-scores by administration method, with lumbar BMD, T-scores being significantly higher in the IV BP group compared to the oral BP group.
Abstract
To examine risk factors of MRONJ and compare whether there is a difference in BMD value depending on the duration of administration, method of administration, and occurrence of MRONJ. We selected 53 patients who were diagnosed with MRONJ at the Ulsan University Hospital and underwent surgery between January 2011 and May 2021. The risk factors are age, sex, systemic disease, location, administration methods, type of drug, duration, local factors and stage. 19 patients, especially those who were diagnosed with MRONJ and underwent BMD, were compared with BMD in femur and lumbar areas according to duration, administration methods. There were many women in all age groups, with 18 in their 70s. There were about twice as many mandibles as the maxilla. It was significantly higher when the IV BPs was administered in cancer patients, and significantly higher when the oral BPs was administered in osteoporosis patients. There was a significant difference between each period in patients taking oral BPs, and the incidence of MRONJ was high when taking them for more than 4 years. There were 35 patients who developed into MRONJ after dentoalveolar surgery. There were significant differences in femur and lumbar BMD, T-scores by administration method, with lumbar BMD, T-scores being significantly higher in the IV BP group compared to the oral BP group.
참고문헌 (12)
- Robert E Marx, "Pamidronate(Aredia)and zoledronate(Zometa)induced avascular necrosis of the jaws : a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)
- Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update", J Oral Maxillofac Surg, 80, pp.920~943 (2022)
- Tohashi K, "Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents", Yonago Acta Med, 59, pp.45~53 (2016)
- Rodan GA, "Bisphosphonate mechanism of action", Curr Mol Med, 2, pp.571~ (2002)
- Pabst AM, "Bisphosphonates’ antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws : influence on microvessel sprouting in an in vivo 3D Matrigel assay", Clin Oral Investig, 18, pp.1015~ (2014)
- Auzina D, "A population-based study of multiple myeloma patients with medication-related osteonecrosis of the jaw", Stomatologija, 21, pp.13~17 (2019)
- Saad F, "Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases", Ann Oncol, 23, pp.1341~ (2012)
- Black DM, "The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis : A randomized second extension to the HORIZON-Pivotal fracture trial(PFT)", J Bone Miner Res, 30, pp.934~ (2015)
- Boonyapakorn T, "Bisphosphonate-induced osteonecrosis of the jaws : prospective study of 80 patients with multiple myeloma and other malignancies", Oral Oncol, 44, pp.857~ (2008)
- Sedghizadeh PP, "Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy", J Am Dent Assoc, 140, pp.1259~ (2009)
- Vahtsevanos K, "Longitudinal cohort tudy of risk factors in cancer patients of bisphosphonaterelated steonecrosis of the jaw", J Clin Oncol, 27, pp.5356~ (2009)
- Roux C, "Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis", Osteoporos Int, 23, pp.1083~1090 (2012)